NeoGenomics achieves record clinical volumes and advances key growth initiatives, including a favorable court ruling for the Radar ST MRD assay launch.

OPERATOR - (00:00:00)

In a table available in the press release we issued this morning and in the slide deck available in the Investors section of our website. I will now turn the call over to Tony.

Tony - (00:00:13)

Thanks Priya. Well, good morning everyone. Thank you for joining us today. I'll begin with a discussion of Q3 highlights and key business growth drivers before turning the call over to Jeff for a deep dive into the financials. We'll then open the call for your questions. During the third quarter of 2025, we again delivered record clinical volumes and revenues while making meaningful progress advancing our NGS and MRD long term growth initiatives, including securing a favorable court ruling in our ongoing litigation with Natera that paves the way for a full clinical launch of our Radar ST MRD assay. I'll cover these initiatives in more detail shortly. Taking a step back for those who may be new to the story, having spent much of my first two quarters as CEO engaged in conversations with key stakeholders, I am as optimistic as ever about the significant opportunities that are in front of us as a leader in cancer testing. Importantly, we continue to differentiate ourselves in the community setting with both hospitals and oncologists where approximately 80% of all cancer care is delivered. We've built a geographically balanced lab network that allows us to be responsive to customer needs, including offering some of the fastest test turnaround times in the industry when faster, more accurate treatment decisions can have a material impact on patient outcomes. Our recent acquisition of Pathline, a New York State approved lab based in New Jersey, gives us a meaningful presence in the Northeast, which is the number three cancer care market in the U.S. We believe the addition of Pathline allows us to offer significantly faster turnaround times, a larger and relevant New York State approved test menu, and an enhanced physician experience. In the Northeast region, where we have historically been underpenetrated, the integration continues to proceed according to the plan that we communicated when we announced the transaction in March, including the validation of critical turnaround time sensitive assays which was completed during the third quarter. We remain positive about the impact that the acquisition will have in accelerating our growth in the Northeast, and we are on track to capture operational efficiencies and synergies that we anticipate will be accretive to profitability beginning in 2026. Together with our world-class commercial team, we have deep relationships with hospitals, cancer centers and oncologists across the country. We're winning the customer experience by enabling precision oncology in the community setting where adoption of next generation testing has historically lagged behind NCI designated cancer centers. Our customers increasingly view us as the partner of choice for all of their testing needs as their patients advance along their cancer care journey. We offer one of the broadest menus in the industry, with more than 500 tests focused solely on oncology. Our menu spans everything from diagnostics to next generation sequencing for therapy selection to MRD for cancer recurrence and monitoring. This makes NeoGenomics an ideal partner for institutions and practices who are looking to consolidate send-out testing to simplify operational workflows and improve patient experience. The therapy selection and MRD markets represent more than $40 billion of addressable market opportunity, both of which are growing rapidly and are relatively underpenetrated. Needless to say, the ongoing investments that we make in R and D, as well as the potential BD partnerships, are focused on these areas.